Industry News Pfizer / Starna Therapeutics BioSpace

Pfizer buys into in vivo CAR T: Starna licensing deal worth up to $2.6B

  • Pfizer takes exclusive rights outside Greater China to three preclinical in vivo CAR T candidates for autoimmune disease from Starna, a China-based RNA biotech.
  • Terms: $330 million upfront, with up to $2.3 billion more in milestones and royalties; Pfizer also gets the platform for immunology and oncology, plus a research collaboration.
  • Starna delivers RNA through a targeted lipid nanoparticle; Pfizer says it is the company's first in vivo CAR T work.
Points Based on public reports

The $330M upfront is a real commitment for three preclinical assets, so Pfizer is paying for the delivery platform, not the programs. In vivo CAR T skips manufacturing and lymphodepletion, but it also has to prove that a targeted LNP reaches T cells cleanly in humans, and that is untested. With peers pausing ex vivo autoimmune CAR T trials after safety events, Pfizer gets a late entry with a cheaper option. It is also another Chinese in-license in a year full of them.